← #nieuws

Dutch Biotech Event brings together people for progress

Last Friday, the Dutch biotech ecosystem came together again to celebrate the power of biotech and the people who try to harness it for progress. With a great line-up of inspiring keynotes and fascinating break-out sessions, this year’s program highlighted once more that people working in biotech will go above and beyond to positively impact the wellbeing of people, animals and our planet. 

Hollandbio’s Annemiek kicked off the event with nearly 300 participants with a warm welcome at the beautiful lakeside venue of Innstyle, Maarssen. She highlighted that progress through biotech depends on three key questions: are we able, allowed, and willing to bring biotech innovations forward? In that sense, the Dutch government vision on biotechnology can be considered a breakthrough as it encompasses all these three aspects – although we still need to turn it from words into concrete action.  

Despite strong support for biotech in both national and European strategies, Annemiek challenged the audience with a pressing question: what’s holding us back? “Too much talk, too many rules, and too little action,” she said, warning that if we don’t act soon, the Netherlands risks losing its leading position. With the EU Biotech Act currently in development, now is the time. As Annemiek put it: “We need to make bold moves, to make real impact.” 

We’ve got some homework to do: pledge your support at www.hollandbio.nl/actnow and share your vision!  

Annemiek concluded with an exciting announcement: the exclusive hollandbio Members Platform is now live! On the platform, our members can find member-only updates, get in contact with other members, find an overview of our events and learn more about our member benefits. Have a look yourself! 

The baton was then handed over to Chretien Herben, who has headed the Venture Challenge for over 20 years now. In recent years, there have been multiple competitions a year, spawning and raising a new generation of biotech entrepreneurs. After short pitches from all the finalists, NeuroNovaTX came out as the winner, developing an innovative intranasal stem cell therapy to treat newborn babies suffering from early life brain injury. 

Annemiek then introduced the first keynote of the plenary program, Jan Smeitink. As CEO of biotech company Khondrion, he shared a deeply personal journey spanning from his early career as a scientist, pediatrician and then professor up until the step into entrepreneurship to try and cure patients with mitochondrial diseases. He shared how, among others, shadows of the past, the right people at the right time, and a bit of luck and passion have led him along the way from science to quite cumbersome negotiations with a technology transfer office to now a company setting up a Phase III clinical trial and actually treating patients. 

During the intermezzo towards the second keynote, Chretien made a comeback but now for the pitches of the BioBusiness Masterclass in its revamped form. This course aims to bring about a new generation of biotech leaders, as it has brought to life lots of startups, entrepreneurs, and professionals in the past. The BioBusiness Masterclass is all about personal development, group cases and competition. The two final teams (MimeCure and Lumox) were given the opportunity to pitch after which MimeCure was announced as the winner. 

The second keynote on the stage was Katelijne Bekers, CEO at MicroHarvest – a German-Portugues biotech company all about delivering better protein ingredients with the help of biotech. She started off in science and started a PhD with the aim of making the world greener but quit that trajectory because she’d rather translate this science from the lab into society. From roles in engineering and scaling up at Corbion and Bio Based Europe Plant, she went on to Ohly where she also did an MBA, in her own words to “be able to talk about biotech in a language that businesspeople understand.” After some contemplation about how she could really make a difference in the world, Kate started MicroHarvest, with her co-founder. They kicked off with the desired endpoint in mind: big clients need hundreds or thousands of kilograms of product for a test trial, while startups mostly only manage twenty kilograms. With the help of modern biotech and a strong focus on process innovation, diversity in people and room for ideas and room for failures to learn from, MicroHarvest has scaled up to production of more than a ton per day within four years with applications in for example, pet food. Katelijne concluded by looking ahead, with the company making the shift from specialty markets to commodity markets and “preparing to build its own production facility – something investors really hate.” 

After a networking break, it was time for the breakout sessions with several themes at the heart of entrepreneurs and companies, of which there were four in total:  

Unlocking boardroom brilliance: how to build an effective board 

This session offered an insightful and interactive discussion on how to build and run effective boards. One key topic was the value and definition of an independent board member, including the challenge of attracting them at an early stage. As Shelley Margetson (V-Bio Ventures) noted, “Independent board members bring a different network and point of view,” and ideally, “if you have an independent board member, make them the chair.” Fred Dom (Seven Pines Holding) emphasized the importance of clarity: “Be clear upfront when a new board member arrives—what type of role they have and what decisions they will be involved in.” He also reminded us that “the CEO is not there to please the board. The CEO’s responsibility is to serve the company.” A memorable takeaway came from Shelley: “Never assume board members will remember what you told them earlier. Bring them back to speed every time, they have more going on.”  

Culture counts: How to build a biotech company people want to work for? 

This session offered a lively and thought-provoking exploration of what makes company culture truly matter. To kick-off the discussion, hollandbio’s Wieteke shared some thoughts on what an innovative culture entails and how to foster great places to work. Then, three panelists offered diverse perspectives from their own cultural journey. Violette Defourt (Rapidemic) shared insights from a startup lens, Marco Fossatelli brought experience from biotech leadership and consultancy, and Sylvia Stam (Galapagos) reflected on culture within a large, publicly traded company. A recurring theme was that culture isn’t static or easily defined; it must be continuously nurtured, especially during change. The panel emphasized that culture should be authentic, lived daily, and embedded in everything from hiring to leadership behavior. Together with the audience, they discussed how to make culture tangible—beyond mission statements—through open dialogue, shared values, and conscious effort. The key takeaway? Culture counts—but only if you make it count. 

Biotech financing trends: Does the winner take it all? 

What are the current financing trends in the biotech investment landscape? The Dutch life sciences sector sees a decline in new biotech company foundation, but an increase in the level of funding amounts raised by established biotech companies, leading to a ‘winner takes all’ effect. Is this effect specifically occurring in the Netherlands, or is it a global trend? Moderator Jan de Kerpel (Van Lanschot Kempen) discussed this together with Thom Frielink (Curie Capital), Prashanthi Ramesh (EQT Life Sciences) and Sijme Zeilemakers (Sapreme Technologies) and a room full of curious biotech professionals. The conclusion? Yes, there were fewer exits and the circle of investments needs to complete before it can start something new. Not every idea has enough upside, there are funds available when you tick all the right boxes. If not, tough times are ahead. 

Synergizing for success: How to profit from your collaborations?   

What does collaboration look like for you? How do you make the most of the collaborations you are a part of, and which shapes can these collaborations take? Under the expert guidance of Marije Martens (Twynstra Gudde), we dove deep into all these questions. Turns out: it matters a lot how a collaboration is set up. Whether it is a very hierarchical design with a clear leader taking the decisions, or a more loosely defined coalition of people trying to reach a shared goal, all models have their place, their value and their caveats. Like one of the attendees shared at the end: “This session really helped me put into perspective why working together doesn’t always run smoothly but also gave me insight in how 1 and 1 can equal 3.”  

We want to thank all speakers, participants, and fellow organizers for making this year’s edition another great success. We hope you enjoyed it as much as we did to meet other biotech professionals and enthusiasts, and exchange the struggles, possibilities and passions of working in this ambitious sector! 

← #nieuws

Nieuw elan in het bestuur van hollandbio 

,

Hollandbio verwelkomt naast nieuwe aanwas in het bestuur ook een nieuwe voorzitter. Tijdens de jaarlijkse Algemene Ledenvergadering voorafgaand aan het Dutch Biotech Event van vrijdag 27 juni, heeft Oscar Goddijn (dsm-firmenich) de voorzittershamer overgedragen aan Jan van Veen (Genmab). Waar Oscar en daarnaast Linda Dijkshoorn afzwaaien als bestuurslid, verwelkomen we tegelijkertijd twee nieuwe leden: Alexander Willemse (BioConnection) en Hella Schmidt (dsm-firmenich).  (English below)

Oscar heeft zich als voorzitter met tomeloze energie en toewijding jarenlang met succes ingezet voor het vergroten van de impact van dat wat hollandbio doet voor de belangen van de Nederlandse biotechsector. Het bestuur, de leden en het bureau van hollandbio bedanken Oscar en Linda voor hun inzet voor hollandbio en de Nederlandse biotech. We zijn beiden enorm dankbaar voor hun inzet, visie en betrokkenheid.

Met Jan van Veen, Vice President Communications and Public Affairs  bij Genmab, krijgt het hollandbio-voorzitterschap een waardig opvolger. Zijn jarenlange ervaring bij diverse bedrijven in de biotechsector en zijn strategische blik maken Jan bij uitstek geschikt voor de voorzittersrol: 

“In de afgelopen drie jaar als lid van het bestuur van hollandbio heb ik van dichtbij kunnen zien hoe groot de impact van onze organisatie is op het beleid en op het netwerk van biotechnologiebedrijven in Nederland. Biotechnologie is de industrie van de 21e eeuw, met oplossingen voor grote vraagstukken op het gebied van voedsel, milieu en gezondheidszorg. 

De biorevolutie gaat door en de enige vraag die we als land volgens mij moeten stellen is: willen we daar deel van uit maken ja of nee?  

Als nieuwe voorzitter van het bestuur verheug ik me op de aankomende jaren. Jaren waarin we als land hopelijk de vele prachtige bedrijven in onze sector de ruimte geven om te groeien. Want dat is wat we nodig hebben: ruimte voor innovatie, groei, en daarmee impact.” 

Ook zijn we trots op de versterking van het bestuur met nieuwe leden Alexander Willemse en Hella Schmidt. Alexander brengt als CEO van BioConnection een scherp inzicht mee in de uitdagingen en kansen waar biotech ondernemers en bedrijven mee te maken krijgen: 

“Als innovatieve CMO en hollandbio-lid van het eerste uur staan we letterlijk en figuurlijk tussen onze klanten: we zien van dichtbij welke stappen biotech- en farmabedrijven moeten zetten om door te groeien. Die unieke positie – gecombineerd met onze diepgaande kennis van de productieketen – wil ik de komende jaren inzetten om samen met hollandbio de volledige keten sterker op de kaart te zetten. Richting overheden, richting investeerders. Want hoe beter die keten functioneert, hoe sneller nieuwe geneesmiddelen de patiënt bereiken. En dat is waar het uiteindelijk allemaal om draait.” 

Hella Schmidt, Senior Vice President Strategy, Marketing & Transformation bij dsm-firmebich, brengt brede ervaring mee op het snijvlak van strategie, innovatie en transformatie binnen de biotech: 

“Ik treed graag toe tot het bestuur van hollandbio omdat ik een diepe passie heb voor innovatie en de kracht van biotechnologie om maatschappelijke uitdagingen aan te pakken. Vanuit mijn rol in strategie, innovatie en transformatie zie ik dagelijks hoe samenwerking tussen wetenschap, industrie en beleid het verschil kan maken. Ik geloof dat hollandbio een unieke positie heeft om deze samenwerking te versnellen en impact te vergroten. Door mijn ervaring en energie in te zetten, hoop ik bij te dragen aan een nog sterkere, toekomstgerichte biotechsector in Nederland.” 

Vanuit het hele hollandbio team: een warm welkom aan alle nieuwe bestuursleden!  

New momentum in hollandbio’s board of directors 

Alongside new additions to the board, hollandbio also welcomes a new chair. During the Annual General Meeting held ahead of the Dutch Biotech Event on Friday, June 27, Oscar Goddijn (dsm-firmenich) officially handed over the chairmanship to Jan van Veen (Genmab). As Oscar and fellow board member Linda Dijkshoorn step down, we are proud to welcome two new members: Alexander Willemse (BioConnection) and Hella Schmidt (dsm-firmenich). 

As chair, Oscar dedicated himself with tireless energy and unwavering commitment to increasing the impact of hollandbio’s efforts on behalf of the Dutch biotech sector. The board, our members, and the hollandbio team sincerely thank Oscar and Linda for their dedication, vision, and engagement. 

With Jan van Veen, Vice President Communications and Public Affairs at Genmab, the chairmanship is in excellent hands. Jan brings years of experience in various biotech companies and a strong strategic perspective — making him the ideal person to lead hollandbio into its next phase.  

“Over the past three years as a member of hollandbio’s board, I’ve seen up close the significant impact our organization has on policy and on the network of biotechnology companies in the Netherlands. Biotechnology is the industry of the 21st century, offering solutions to major challenges in food, the environment, and healthcare.” 

We are equally proud to strengthen the board with the addition of Alexander Willemse and Hella Schmidt. As CEO of BioConnection, Alexander brings valuable insight into the challenges and opportunities biotech companies face: 

“As an innovative CMO and founding member of hollandbio, we are literally and figuratively close to our clients: we see up close what biotech and pharma companies need to grow. I want to use that unique position — along with our deep knowledge of the production chain — to help hollandbio strengthen the entire chain’s visibility and impact. Towards governments, towards investors. Because the better that chain works, the faster new medicines reach patients. And that’s what it’s all about in the end.” 

Hella Schmidt, Senior Vice President Strategy, Marketing & Transformation at dsm-firmenich, brings broad experience at the intersection of strategy, innovation, and transformation in biotech: 

“I’m excited to join hollandbio’s board because I have a deep passion for innovation and for biotechnology’s power to address major societal challenges. In my role, I see every day how collaboration between science, industry, and policy can make a real difference. I believe hollandbio holds a unique position to accelerate this collaboration and amplify its impact. By contributing my experience and energy, I hope to help build an even stronger and future-oriented biotech sector in the Netherlands.” 

From the entire hollandbio team: a warm welcome to all our new board members! 

← #nieuws

Hollandbio welcomes Hamilton as a new member

Hollandbio connects, represents, and supports the Dutch life science sector. We are very proud that we already represent 260 companies: from start-ups, small and medium-sized companies to large companies, active in health, food, or the biobased economy. Today, we are happy to introduce Hamilton, a global leader in intelligent sensor technology dedicated to solving bioprocess and biopharma challenges. Hamilton: “With a pioneering spirit and decades of expertise, we empower biotech manufacturers with our sensing solutions that enhance process understanding. This leads to greater confidence during critical decision-making, thereby improving process consistency and product yield.”

“Our portfolio encompasses a comprehensive range of measurement technologies for critical process parameters (CPPs) and key performance indicators (KPIs), including pH, ORP (redox potential), dissolved oxygen (DO), dissolved CO₂, conductivity, viable cell density, and total cell density. These sensors are engineered for high-performance monitoring in both upstream and downstream processes, delivering accurate, real-time data that supports optimization, quality assurance, and regulatory compliance.”

“Since introducing our first sensor in 1989, Hamilton has continuously set industry benchmarks for innovation and reliability. Today, our offering includes not only advanced sensors but also a full assortment of accessories—including housing, transmitters, cables, calibration buffers, and standards—to ensure seamless integration and long-term operational efficiency. Our Arc technology, featuring integrated digital intelligence and wireless connectivity, transforms traditional sensors into smart devices, enabling predictive maintenance, automated calibration tracking, and simplified data management. And to support the growing demand for flexibility and contamination control, we also offer single-use sensor solutions that meet the stringent requirements of modern biopharmaceutical production.”

“Hamilton is truly a global partner, with a strong international presence and local representatives across Europe, North America, and Asia. This ensures close collaboration with our customers, fast response times, and tailored support in every region. Whether you’re producing life-saving therapeutics or optimizing microbial fermentation, our solutions help ensure product quality, regulatory compliance, and operational excellence.”

← #nieuws

Dutch Biotech was buzzing in Boston

,

Orange was the color of innovation last week in Boston, as Dutch biotech made waves at BIO 2025. Over 20.000 innovators, investors, and industry leaders from across the globe gathered on the other side of the Atlantic Ocean to work on a better future for people, animals, and the planet. And at the heart of it, we were proud to represent and connect with the vibrant Dutch biotech ecosystem together with colleagues from Health~Holland and the Netherlands Foreign Investment Agency (NFIA). Besides more than 100 Dutch delegates from 70 different biotech companies, this year we were joined by special guests from the Dutch Ministries of Economic Affairs, and Health, Welfare and Sport — a strong signal of the Netherlands’ commitment to global biotech leadership. Together we explored how The Netherlands can turn its biotech ambitions into bold and actionable leadership.

We kicked off the week with a buzzing Dutch welcome reception on Sunday evening at local beer brewery Trillium’s Fort Point taproom. During this special Boston edition of our ‘Hollandbio komt naar je toer’ event series, the Dutch delegation had the opportunity to catch up with familiar faces and share ambitions, setting the tone for the exciting week ahead.  

From Monday to Thursday, a steady stream of curious visitors from all over the world stopped by the Dutch Pavilion to connect, energize and discover what makes the Netherlands a true biotech hotspot. The absolute highlight? Our Dutch Networking Reception on Tuesday evening, complete with the much-anticipated bike raffle. After an inspiring speech by Sipko Mülder, Management Team member of Pharmaceutical products and Medical technology at the Ministry of Health, Welfare and Sport, he and Annemiek Verkamman took the stage to announce the lucky winner: Pardis Saffari, Director of Economic Opportunity & Development at the City of Cambridge. Huge thanks to Loyens & Loeff for sponsoring the bike. We hope to spot it cruising through Boston next time we visit! 

Meanwhile, the Dutch ministry representatives crisscrossed the city — by bike and by cab — to meet with key players in Boston’s biotech ecosystem. From strategy sessions at the Massachusetts Life Sciences Center and Massachusetts Institute of Technology, to deep dives at the Broad Institute and Cambridge Innovation Center, they gathered valuable insights on how to translate scientific breakthroughs into real-world impact. At the BIO itself, they met with members of the European Commission currently working on the EU Biotech Act for an additional European perspective. And Jeroen Heijs, Deputy Director of Innovation and Knowledge at the Ministry of Economic Affairs, participated in a panel discussion hosted by the European Innovation Council on how collaboration works in today’s biotech pipeline. We’re sure these countless meetings and inspiring activities help the policy makers to further shape and sharpen the Dutch biotech vision. 

A heartfelt thank you to everyone who joined us in Boston — your energy, ideas, and ambition made this another unforgettable BIO. We’re already looking forward to continuing the momentum at BIO Europe Vienna in November, BIO Europe Spring Lisbon in March or the BIO US San Diego in June next year. Until then, keep innovating!

← #nieuws

EU Biotech Act call for evidence: four asks to make biotech thrive 

, ,

Europe worked hard to become a leader in biotech. But while the rest of the world is taking the next step, we are blocking ourselves. Innovations get stuck in outdated rules and fragmented regulations, talent moves elsewhere, and other continents capitalize on European breakthroughs. If we don’t act now, Europe not only loses its frontrunner’s position, but also the societal and economic benefits that biotech can deliver: new medicines, smarter and cleaner products and a resilient economy.  

While the US and China are competing over pole position, the EU aims to step up its game when it comes to biotech, too. The EU Biotech Act, to be launched next year, is one the instruments to reinstate Europe as a biotech powerhouse. At hollandbio, we welcome the EU Biotech Act as a long-awaited opportunity to restore Europe’s leadership in biotechnology and strengthen our biotech innovation ecosystem—from invention all the way to uptake.   

In our overarching EU Biotech Act position paper, we state what we think is needed to ensure European biotech can thrive. Building on this, hollandbio submitted four key asks for the European Commission’s recent Call for Evidence, a consultation to gather input from stakeholders and experts to shape the EU Biotech Act legislative proposal. 

To ensure biotech can thrive in Europe, we urge policymakers to focus on four key priorities: 

  • Boosting biotech with an integrated approach; 
  • Investing in progress driven by frontrunners; 
  • Paving the way to market entry; 
  • Removing barriers for implementation and uptake. 

In these uncertain time, one thing is clear: the coming years are of crucial importance for the success of biotech. From curing incurable diseases to creating eco-friendly materials and ensuring food security, if we want to pass on a livable world to future generations, biotech is an essential part of the solution.  

What would you act for? 

Have you ever faced funding gaps, regulatory delays, or an uneven playing field? Then this is your moment to speak up! Share your vision for the future of European biotech by joining the conversation on LinkedIn by using #EUBiotechAct.  

← #nieuws

Marit Heblij voor even weer terug bij hollandbio 

Konnichiwa! Na bijna twee jaar genieten van Japan ben ik niet alleen weer terug in Nederland, maar ook bij hollandbio. En dat voelt als thuiskomen! Ik heb ontzettend veel zin om de komende maanden het programmateam van het programma Technologie voor een duurzame toekomst te ondersteunen, want de wereld smacht naar jullie slimme biotech innovaties.  

Zin om bij te kletsen of kennis te maken? Uiteraard ben ik bij het Dutch Biotech Event op 27 juni, maar een kop koffie op kantoor kan natuurlijk ook. Stuur me een mailtje en ik kom bij je terug op de lijn.  

Biotech maakt wereldwijd het leven beter, ook in Japan (en nee dan heb ik niet alleen over Miso ramen, sake of natto). De bovenstaande foto’s zijn genomen in het Japan paviljoen op de Expo 2025 in Osaka, waarbij ‘the circle of life’ centraal staat en (hello kitty-) micro-organismen volop in de schijnwerpers.  

← #nieuws

Current state of biotech: hollandbio’s Wieteke at Johnson & Johnson’s event ‘Paths to the patient’ 

Last Tuesday at Johnson & Johnson’s event ‘Paths to the patient’, hollandbio’s Wieteke delivered a keynote about the current state of Dutch biotech. With a room full of frontrunners, the message was clear: it’s time to act (super) now. Wieteke outlined three key drivers of innovation: the urgent global challenges like unmet medical needs; the unprecedented potential of bioscience combined with computing and AI; and the drive of bold biotech entrepreneurs. These key drivers are not just shaping the future — they are transforming the way we feed and fuel the world.

Hollandbio’s Wieteke shared her perspective: “These are exciting times to be in biotech: as we are learning more and more about the ingenuity of nature, clever scientists and entrepreneurs are not just eager to publish their findings — they are determined to embark on the bold journey to turn this knowledge into life-saving solutions for patients”.  

While these are challenging times for biotech companies,  we’ve never seen more unity, willingness, and urgency to do what is needed to let the Dutch and European biotech ecosystem flourish. With the ambitious national Dutch vision on biotechnology and the upcoming EU Biotech Act in mind, the moment is now to deliver on our promise to make life better with the power of biotech. 

← #nieuws

Kabinet gevallen, hollandbio biodieselt door 

,

Met het opzeggen van de samenwerking door Geert Wilders en het vertrek van zijn PVV-bewindslieden is kabinet-Schoof I elf maanden na aantreden al demissionair. Nieuwe verkiezingen staan op de rol voor 29 oktober, en hollandbio zal met hernieuwde inspanning weer voor de biotech sector opkomen. Heb je ideeën of wil je meepraten over nieuwe plannen, laat het ons dan vooral weten. Eerst zetten we de resultaten uit de afgelopen tijd op een rij. 

Tussen het aantreden van de laatste paar kabinetten zat telkens een demissionaire periode van bijna een jaar, langer dan het huidige kabinet heeft gezeten. In deze demissionaire status behandelt een kabinet alleen nog lopende zaken en staan omstreden of controversiële kwesties in de ijskast. Van amper twee jaar geleden weten we nog dat een demissionair kabinet terughoudend is met grote nieuwe plannen. Op veel grote dossiers dreigt dan stilstand, en dus is het zaak om het ijzer te smeden als het heet is. In korte tijd heeft hollandbio zich gelukkig verrassend succesvol kunnen manifesteren.  

Overheid heeft nu visie op biotech 

Kabinet-Schoof I begon nog wel met grote woorden – en een paar tegenstrijdige daden. Gelukkig konden we een half jaar later het meest sprekende succes noteren. Na een lang traject met allerlei stippen en stappen hebben afgelopen april maar liefst zeven bewindspersonen hun handtekening gezet onder de Rijksbrede visie op biotech. Als we samenwerken, krijgen we wat voor elkaar, en dat geldt natuurlijk ook tussen ministeries. Biotech staat goed op de kaart, zo lazen we eerder ook al in de Nationale Techstrategie – een van onze andere duidelijke asks uit hollandbio’s verkiezingsmanifest, dat we de komende tijd van de nodige updates gaan voorzien. 

In nauw contact met Kamerfracties 

Ook buiten het kabinet zaten we niet stil, en zijn we met coalitiefracties op bezoek gegaan in Wageningen. De Kamer sprak brede politieke steun uit voor onder meer fermentatie, NGT’s en durfkapitaal – met proeverijen voor innovatieve fermentatie tot gevolg. En alhoewel we er liever voor zorgen dat Nederland een stukje beter in plaats van minder slecht wordt, sprongen we met succes op de bres voor cel- en gentherapieën.   

Voorafgaand aan verkiezingen met partijen in gesprek 

Meer weten over de inzet van hollandbio en hoe we opkomen voor de Nederlandse biotech? Je leest het in onze recente highlights. En heb je ideeën of wil je meepraten over nieuwe plannen? Laat het ons vooral weten! In aanloop naar de verkiezingen zullen we met verschillende partijen in gesprek gaan zodat zij weten wat de Nederlandse biotech nodig heeft om een koploper te blijven. Vervolgens zullen we de partijprogramma’s van de politieke partijen weer uitpluizen en voor jullie met biotech in het achterhoofd op een rij zetten. 

Nog niet meegenomen: 

← #nieuws

Your Path, Your Impact: hollandbio’s Annemiek at the BCF Career Event 

Last week at the BCF Career Event 2025, hollandbio’s Annemiek delivered an inspiring keynote titled “Your Path, Your Impact”. Drawing from her own biotech journey, Annemiek shared powerful insights on how to build a meaningful career in biotech. She emphasized that now is the perfect time to step into the biorevolution, as we stand on the brink of transformative change. Her talk encouraged attendees to reflect on what drives them, understand their unique strengths and recognize the value of collaboration in teams. Annemiek also explored how understanding decision-making processes and creating a “great place to work” culture can shape both personal and organizational success. Her message on building a meaningful biotech career was clear: know yourself, leverage the knowledge of others, and take ownership of your career path—wherever you are in your journey. 

← #nieuws

Hollandbio x Health and Innovation District: a successful edition of ‘hollandbio komt naar je toer’ in Amsterdam 

Last Thursday, ‘hollandbio komt naar je toer’ arrived in Amsterdam, where 70 biotech professionals gathered for drinks and bites at Sanquin, in Amsterdam. This edition was organized together with Health and Innovation District (HID). Wigard Kloosterman, CEO of biotech startup Tzu Cancer Therapeutics delivered a short pitch about revolutionizing cancer treatments through cutting-edge, personalized solutions. We’d like to thank all guests for attending and HID for co-organizing this edition!  

Stay tuned for the photos!

Next up on our tour calendar are the Boston edition on June 15th & Groningen edition on July 7th. We hope to see you there or at one of the other networking events at local biotech hubs throughout the country this year!